Clinical Trial Search

Primary: Postprandial Serum Glucose in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin Averaged Per Subject — 3.8; -1.8; 7 mg/dL — p=0.000016

Primary: Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours — 301.09; 258.66; 248.63; 274.13 mmol x min/L — p=0.1146

Primary: Renal Clearance of D-chiroinositol (DCI) at 12 Days — 4.75; 5.16 ml/min

Primary: Fasting Insulin — 12.7; 13.1; 16.4; 13.9 μU/mL

Primary: Change in HbA1c — -0.20; -0.53; -0.31 % of glycated haemoglobin — p=0.0039

Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min

Primary: Glucagon Response to Induced Hypoglycemia — 4.8; 8.8; 5.8; 4.2 pg/mL

Primary: Insulin Sensitivity — 0.1; 0.07 mL/kg/min per uU/mL

Primary: Glycemic Control — 10.7; 10.9 mmol/L — p=0.677

Primary: Change in Glycated Haemoglobin (HbA1c) [Percentage Point (%-Point)] — -1.33; -1.15 Percentage point of HbA1c — p=0.0818

Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage

Primary: Maximum Insulin Concentration (Cmax) - First Phase Response — 233; 689; 74.3; 401 picomole per liter (pmol/L) — p=<0.001

Primary: Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c) — 8.70; 8.69; -1.46; -1.41 percent of HbA1c — p=0.551

Primary: Insulin Sensitivity — 3.06; 3.33 units on a scale

Primary: Hepatic Glucose Production (Co-primary Outcome) — 2.0; 2.0; 2.1; 1.8 mg/kg-minute

Primary: Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c) — 8.79; 8.77; -1.52; -1.31 percent of HbA1c — p=0.026

Primary: Hemoglobin A1c (HbA1c) at 36 Week Endpoint — 7.66; 7.49 percent HbA1c — p=0.097

Primary: Difference in Glucose Tolerance Between Morning at 7:00 AM and Evening at 7:00 PM — 163; 203 mg/dl — p=0.02

Primary: Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentrations — 0.27; 0.17 micromole per Liter (μmol/L)

Primary: Change in Weekly Mean Blood Glucose From Week 4 to Week 16 — 4.6; 8.1; 29.5 mg/dL

Primary: Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF]) — 8.48; 8.47; -1.21; -1.43 percent of glycosylated hemoglobin

Primary: Mean Blood Glucose of All Readings — 157.2; 181.8 mg/dL

Primary: Percentage Change in Trunk Fat Mass (Defined as Peripheral Fat Ratio) — 0.366; 1.011 percent change — p=0.849

Primary: Adiponectin — -0.71; -7.52 µg/mL

Primary: Insulin Sensitivity — 273; 817 nmol/kg FFM/min /(µU/mL Insulin)

Primary: The Percentage of Intent to Treat Participants Randomized and Treated in Each Arm Who Had Lab-measured A1c <6.5% at 24 Weeks of Treatment — 47; 12 percentage of…

Primary: Efficacy Index (%EI) — 82.76; 43.66; 14.58 percentage (%)

Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year

Primary: Number of Hypoglycemia Episodes After the Transition Period From Intravenous Insulin to Subcutaneous Insulin Between 2 Treatment Groups — 8; 26 number of hypoglycemia…

Primary: Adjusted Mean Change in HbA1c From Baseline to Week 24 — 0.03; -0.87 percentage of hemoglobin — p=<0.0001